Patents by Inventor Marja van Meijer

Marja van Meijer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding molecules for the treatment of myeloid cell malignancies
    Patent number: 8632985
    Abstract: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention, and/or treatment of neoplastic disorders and diseases.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: January 21, 2014
    Assignee: Crucell Holland, B.V.
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianns Q. Bakker, Alexander Berthold Hendrik Bakker
  • BINDING MOLECULES FOR THE TREATMENT OF MYELOID CELL MALIGNANCIES
    Publication number: 20120270802
    Abstract: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention, and/or treatment of neoplastic disorders and diseases.
    Type: Application
    Filed: May 17, 2012
    Publication date: October 25, 2012
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianns Q. Bakker, Alexander Berthold Hendrik Bakker
  • Binding molecules for the treatment of myeloid cell malignancies
    Patent number: 8268966
    Abstract: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: September 18, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
  • Human binding molecule against CD1a
    Patent number: 7968092
    Abstract: The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of neoplastic disorders and diseases.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: June 28, 2011
    Assignees: Crucell Holland B.V., The Johns Hopkins University
    Inventors: Mark Throsby, Marja van Meijer, Wilfred T. V. Germeraad, Robert J. Arceci, Ada M. Kruisbeek
  • Binding molecules for the treatment of myeloid cell malignancies
    Publication number: 20100184671
    Abstract: Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 22, 2010
    Applicant: Crucell Holland B.V.
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
  • Binding molecules for the treatment of myeloid cell malignancies
    Patent number: 7741443
    Abstract: The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: June 22, 2010
    Assignee: Crucell Holland B.V.
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
  • Human binding molecule against CD1A
    Publication number: 20060257397
    Abstract: The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of neoplastic disorders and diseases.
    Type: Application
    Filed: March 23, 2006
    Publication date: November 16, 2006
    Applicants: Crucell Holland B.V., The Johns Hopkins University
    Inventors: Mark Throsby, Marja van Meijer, Wilfred Germeraad, Robert Arceci, Ada Kruisbeek
  • Binding molecules for the treatment of myeloid cell malignancies
    Publication number: 20060177451
    Abstract: The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.
    Type: Application
    Filed: December 22, 2005
    Publication date: August 10, 2006
    Applicant: Crucell Holland B.V.
    Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Bakker, Alexander Bakker